The Coriell Personalized Medicine Collaborative (CPMC), a research initiative exploring the utility of genetic information in the clinical setting, has published a study and identified six noteworthy genes that affect human sleep duration.
The Coriell Institute for Medical Research today announces the in-licensing of PluriTest, a cost-effective, accurate, animal-free bioinformatics assay for determining the pluripotency of human induced pluripotent stem cells (hiPSC).
The Coriell Institute for Medical Research is deeply saddened to announce the sudden passing of its President and CEO, Michael Christman, PhD.
The Coriell Institute for Medical Research is proud to announce the release of new samples representing N-glycanase deficiency, caused by a mutation on the NGLY 1 gene, also known as Congenital Disorder of Deglycosylation (CDDG). These extraordinarily well characterized samples come from the National Human Genome Research Institute (NHGRI) Undiagnosed Disease Program (UDP) and will be distributed from the National Institute for General Medical Sciences (NIGMS) Human Genetic Cell Repository (HGCR) housed at Coriell.
The Coriell Institute for Medical Research's quality managment system has been certified to the updated ISO 9001:2015 standards.
Coriell Institute for Medical Research today announced the promotion of two of its scientists to new leadership roles. Alissa Resch, PhD, is now the Institute’s Chief Scientific Officer and Nahid Turan, PhD, is now Chief Laboratory Officer. Drs. Resch and Turan previously served as Director of Biobanking Operations and Director of Laboratory Operations, respectively.
Researchers from the Coriell Institute for Medical Research will present preliminary research findings at the Military Health System Research Symposium (MHSRS) in Kissimmee, Florida this week. The Coriell scientists will disclose and discuss their work through both posters and breakout session presentations.
The Coriell Institute for Medical Research, Cooper University Health Care and Cooper Medical School of Rowan University (CMSRU) are launching the Camden Opioid Research Initiative (CORI), a first-of-its-kind undertaking to investigate the genetic and biological factors that contribute to the development of opioid use disorder (also referred to as opioid dependence or addiction). Opioid overdoses continue to climb in New Jersey and nationally and the opioid addiction epidemic is one of the most urgent public health concerns of our time. This year is the deadliest year of this epidemic in the Garden State.
New research from scientists at the Coriell Institute for Medical Research shows that some individuals whose bodies metabolize ibuprofen more slowly – causing the drug to be present at higher levels than intended – intuitively self-correct their dose without knowing their genetic makeup.
Jean-Pierre Issa, MD, a world-renowned expert in the epigenetics of cancer and director of Temple University’s Fels Institute for Cancer Research and Molecular Biology, will join the Coriell Institute for Medical Research as its new President and Chief Executive Officer, Coriell’s Board of Trustees Chairman Robert Kiep, III, announced today.
Jean-Pierre Issa, MD, a world-renowned expert in the epigenetics of cancer and director of Temple University’s Fels Institute for Cancer Research and Molecular Biology, will join the Coriell Institute for Medical Research as its new President and Chief Executive Officer, Coriell’s Board of Trustees Chairman Robert Kiep, III, announced today.
The Coriell Institute for Medical Research today announced it is expanding its leadership team by welcoming two skilled scientists to fill two new roles. Jaroslav Jelinek, M.D., Ph.D., will serve as the Institute’s new Chief Research Officer and Jozef Madzo, Ph.D., will join the Institute as its new Director of Bioinformatics. Both are scheduled to start on Feb. 28.
The Coriell Institute for Medical Research received the inaugural Innovation Award from the Cooper’s Ferry Partnership at its annual meeting on Tuesday, March 5. This distinction recognizes Coriell’s role as a unique and critical resource to the global research community and its legacy of scientific foresight.
The Coriell Institute for Medical Research is now participating in a prestigious SU2C Catalyst® grant from Stand Up To Cancer for the study of epigenetic therapy in treating urothelial cancer, a common form of cancer typically found in the bladder. Part of the project grant was moved to Coriell following its hiring of Jean-Pierre Issa, MD, as its new President and Chief Executive Officer.
Patients with acute myeloid leukemia (AML), a leukemia which arises from bone marrow tissue, often see remission following their initial treatment, but for patients whose cancer returns, there are few options. One such option is guadecitabine, a novel DNA hypomethylating drug which slows problematic changes to a person’s epigenetic profile, but the drug is ineffective in a select number of relapsed or refractory AML patients and there has not been a way to determine who stands to benefit and who does not. However, researchers from the Coriell Institute for Medical Research have found certain biomarkers which can indicate a patient’s likelihood for success. Their findings were published in Clinical Epigenetics in July.
The five-year award will support the NINDS Human Genetics Resource Center, a collection of biological samples and corresponding demographic, clinical, and genetic data made available to qualified researchers around the world. This repository includes samples from subjects with various diseases – such as cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette Syndrome.
Shoghag Panjarian, PhD, a research scientist at the Coriell Institute for Medical Research, has been awarded a grant from the W. W. Smith Charitable Trust to support her search for epigenetic factors that contribute to the development and growth of breast cancer.
Obesity is among the most common complex diseases in the United States and has been a stubborn public health challenge for decades. Its causes are wide ranging, but genetic heritability is increasingly understood to be an influential factor in determining a person’s risk for the disease. Coriell researchers have found a new genetic indicator of obesity risk and bolstered the understood importance of one gene’s role in obesity risk.
The Allen Institute has extended its contract with the Coriell Institute for Medical Research for the storage and distribution of its Allen Cell Collection, a cutting-edge collection of gene-edited human induced pluripotent stem cell lines. This collection was launched in 2016 with five cell lines, and since has grown to include more than 40 lines. The new agreement will continue this relationship for an additional three years.
The newly awarded $8.6 million funding keeps Coriell in place as the trusted steward of this collection and includes the addition of new innovative products to expand the collection. The NIA Aging Cell Repository was established at Coriell in 1974 and Coriell has continuously managed this unique resource ever since.
The Coriell Institute for Medical Research has been awarded a $9.2 million grant through an open competition from the National Institute of General Medical Sciences (NIGMS). This five-year award keeps Coriell in place as the steward of the NIGMS Human Genetic Cell Repository, a world-renowned collection of high quality cell lines and DNA samples representing genetic diseases, distinct human populations around the world, and more.
Answering the growing need for additional testing, and in direct response to shortages encountered in testing kit supply pipelines, the Coriell Institute for Medical Research is now offering services to create viral testing collection tubes containing different media and/or buffer formulations, for use in COVID-19 testing kits. Coriell is also exploring the feasibility of saliva as a means for testing for the new coronavirus.
The Coriell Institute for Medical Research has added a new collection of stem cells to its biobank offerings. The new collection is a result of a collaboration between Coriell and the Rett Syndrome Research Trust (RSRT) and consists of 10 lines of human induced pluripotent stem cells created from blood donated by individuals with Rett syndrome.
The National Human Genome Research Institute has renewed its collaborative agreement with the Coriell Institute for Medical Research. For another five years, Coriell will continue to manage the NHGRI Sample Repository for Human Genetic Research, a collection of cell lines and DNA for use in research around the world.
The Coriell Institute for Medical Research and Van Andel Institute (VAI) have been awarded a prestigious Specialized Programs of Research Excellence (or SPORE) grant from the National Cancer Institute (award P50CA254897). The five-year grant valued at an estimated $12.4 million will support nearly 20 scientists as they work to improve epigenetic therapies for cancer. The project is co-led by Coriell’s President and CEO Jean-Pierre Issa, MD, Van Andel Institute’s Chief Scientific Officer Peter A. Jones, PhD, DSc (hon), and Johns Hopkins University and VAI’s Stephen Baylin, MD.
The NIGMS Human Genetic Cell Repository (HGCR) and NHGRI Sample Repository for Human Genetic Research (SRHGR) now offer high molecular weight (HMW) DNA samples isolated from cell lines in the collections. HMW DNA is useful for long-read next-generation sequencing and studies that investigate large-scale genomic variation such as structural variation.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right